STOCK TITAN

Edesa Biotech Inc - EDSA STOCK NEWS

Welcome to our dedicated news page for Edesa Biotech (Ticker: EDSA), a resource for investors and traders seeking the latest updates and insights on Edesa Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Edesa Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Edesa Biotech's position in the market.

Rhea-AI Summary
Edesa Biotech secures C$23 million commitment from the Government of Canada for Phase 3 clinical study of EB05
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
80.74%
Tags
none
-
Rhea-AI Summary
Edesa Biotech, Inc. (NASDAQ:EDSA) announces a one-for-seven reverse share split of its common shares. The split will not affect ownership percentage or voting power, except for fractional shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.69%
Tags
none
-
Rhea-AI Summary
Edesa Biotech's EB05 (paridiprubart) demonstrated a significant 84% reduction in the risk of dying among critically ill patients with severe respiratory disease, according to Phase 2 substudy data. The company has initiated a Phase 3 study and received Fast Track designation from the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.86%
Tags
clinical trial
Rhea-AI Summary
Edesa Biotech, Inc. (Nasdaq:EDSA) Reports Positive Results from University Study and Financial Results for Q3 and 9 Months Ended June 30, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.26%
Tags
earnings
-
Rhea-AI Summary
Edesa Biotech, Inc. (NASDAQ:EDSA) will participate in a Fireside Chat and host one-on-one meetings at the Canaccord Genuity 43rd Annual Growth Conference in Boston from August 7-10, 2023. The Fireside Chat between Edesa's CEO and a Canaccord analyst will take place on August 10, 2023 at 12:00 pm ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.37%
Tags
earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
none
Edesa Biotech Inc

Nasdaq:EDSA

EDSA Rankings

EDSA Stock Data

13.30M
2.33M
18.85%
10.9%
0.56%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Markham

About EDSA

founded in 2015, edesa biotech brings innovative new treatments for dermatological and anorectal diseases. late-stage prescription drugs developed by edesa biotech aim to help patients who experience limited treatment options. edesa biotech's focus on dermatology is led by an experienced team that have licensed global rights to clinical stage assets for dermatology and anorectal indications.